from BayWa AG (isin : DE0005194062)
EQS-Adhoc: BayWa AG: Impairment tests lead to extraordinary depreciation of € 222.2 million (impairment tests in accordance with IAS 36)
EQS-Ad-hoc: BayWa AG / Key word(s): Half Year Report
BayWa AG: Impairment tests lead to extraordinary depreciation of € 222.2 million (impairment tests in accordance with IAS 36)
27-Sep-2024 / 12:48 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The impairment tests that became necessary led to non-cash impairment losses of
€ 222.2 million, which were recognised as depreciation in the Half-Year Financial Statements 2024. At € 171.5 million, the largest share was attributable to BayWa r.e. AG, a 51% subsidiary of BayWa AG. These depreciations have no negative impact on the BayWa Group’s ongoing restructuring efforts and the implementation of the restructuring concept currently being developed.
The full Half-Year Financial Statements 2024 will be published today on the BayWa Group website.
Contact:
Josko Radeljic, BayWa AG, Head of Investor Relations,
tel. +49 (0)89/92 22-38 87, Fax +49 (0)89/92 12-38 87,
e-mail: josko.radeljic@baywa.de
End of Inside Information
27-Sep-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
Language: | English |
Company: | BayWa AG |
Arabellastraße 4 | |
81925 Munich | |
Germany | |
Phone: | +49 (0)89/ 9222-3691 |
Fax: | +49 (0)89/ 9212-3680 |
E-mail: | presse@baywa.de |
Internet: | www.baywa.com |
ISIN: | DE0005194062, DE0005194005, |
WKN: | 519406, 519400, |
Listed: | Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange |
EQS News ID: | 1997511 |
End of Announcement | EQS News Service |
1997511 27-Sep-2024 CET/CEST